At ELRIG’s Drug Discovery 2026, the Drug Discovery News team spoke with Sanj Kumar, Chief Executive Officer at ELRIG, about the evolving drug discovery landscape and the importance of collaboration in driving innovation. As the boundaries between academia, biotechnology, and pharmaceutical research continue to become more open, partnerships across these sectors are creating opportunities to advance promising targets and explore a wider range of therapeutic approaches.
In this interview, Kumar discusses how ELRIG brings the drug discovery community together, supports researchers through mentorship and early-career development initiatives, and fosters connections that can lead to new ideas and collaborations. He also reflects on the challenges facing life sciences professionals amid industry restructuring, the growing role of diverse therapeutic modalities beyond small molecules, and the technologies needed to address unmet medical needs and advance future drug discovery efforts.








